MONOCLONAL ANTIBODIES FOR CANCER DIAGNOSTICS

Areas of Application

Early diagnostics of cancer and leukemia. Differential diagnostics of tumors. Immune status evaluation. AIDS monitoring. Monitoring of the therapy effectiveness

Specification

The kits of purified monoclonal antibodies produced by hybridomas. The hybridoma collection includes producers of monoclonal antibodies against CD3, CD4, CD7, CD8, CD10, CD13, CD15, CD16, CD20, CD22, CD25, CD27, CD34, CD37, CD38, CD43, CD45, CD45RA, CD48, CD54, CD56, CD66e, CD95, CD150, CD227, CD326, HLA-ABC, HLA-DR, kappa and lambda light Ig chains, pan-cytokeratin, cytokeratin-18, p53, and antigen of proliferating cells IPO-38. This antibody panel has been recorded in the State Register of Medical Equipment and Medical Devices of Ukraine and approved for the application in medical practice (permanent license)

Advantages

There are no analogs in Ukraine. The specificity and quality of monoclonal antibodies are as good as those of the foreign analogues, but have a substantially lower price


Stage of Development. Suggestion for Commercialization

IRL8, TRL7

Monoclonal antibodies manufacture, purification, specificity testing, supply, quality assurance, and staff training, upon request

IPR Protection

IPR1, IPR3



Application of monoclonal antibodies in immunofluorescent microscopy



Catalog of monoclonal antibodies

Contact Information

Tatiana V. Pyatchanina, RE Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology of the NAS of Ukraine; +38 044 259 01 67, e-mail: tanya_pyatchanina@ukr.net